PharmaMar Group reports a 27% increase in recurring business, revenues plus royalties, in 2021, to €165 million

- **Operating profit, discounting the effect of the Jazz Pharmaceuticals milestones, increased by 57%.**
- **In 2021, the PharmaMar Group accrued US$25 million (€22 million) for a commercial milestone from Jazz Pharmaceuticals sales in the United States.**
- **Total Group revenues amounted to €230 million.**
- **The Group is cash generative and closed 2021 with a cash and cash equivalents position of €212 million.**
- **Attributable net income amounted to €93 million.**
- **The Group's Board of Directors will propose the payment of a dividend of €0.65 per share, 8% higher than last year's dividend.**

Madrid, February 28th, 2022. – To December 31st, 2021, PharmaMar Group (MSE: PHM) reported recurring revenue growth of 27% to €165 million. These revenues are the sum of net sales plus royalties received for sales.

The increase in recurring revenues in 2021 is due to the good performance of the oncology business. To year-end, oncology sales revenues totaled €119 million, an 18% increase compared with the sales recorded the previous year. Royalty revenues grew by 162% to €41 million[1]. This strong growth is mainly due to royalty revenues received from our partner in the United States, Jazz Pharmaceuticals, for sales of Zepzelca® (lurbinectedin).

In the case of non-recurring revenues from licensing agreements, these mainly relate, in both 2020 and 2021, to the licensing agreement entered into with Jazz Pharmaceuticals, and total €65 million in 2021 and €140.3 million in 2020. License

[1] As our partner, Jazz Pharmaceuticals, has not yet reported its financial results for 2021, the royalties recorded in the fourth quarter of 2021 are an estimate based on our available information.

revenues in 2021 include the accrual of US$25 million (€22 million) from Jazz Pharmaceuticals for achieving certain commercial targets.

The difference in these revenue between years is due to the accounting recognition of the receivables collected in 2020 for the signing of the agreement with Jazz and for the approval of lurbinectedin in the US.

Eliminating the effect of the collections from the lurbinectedin license to Jazz Pharmaceuticals in both 2021 and 2020, PharmaMar Group's operating profit in 2021 would have increased by 57% with respect to 2020.

In the molecular diagnostics segment, GENOMICA, reported net revenues of €5 million at the end of 2021, compared with €13 million in 2020. This difference was mainly due to lower revenues from Covid-19 tests, PCR, lateral flow and antibody tests, as a result of increased competition, which has led to a significant decrease in the prices of these tests.

In 2021, the Group generated operating cash of €26 million. It should be noted that this cash generation followed an investment of €72 million in R&D, an increase of 34% compared to the resources devoted to this, the previous year.

One of the PharmaMar Group's most important clinical trials is LAGOON, which will evaluate lurbinectedin for treating patients with relapsed Small-Cell Lung Cancer which commenced in 2021.

If successful, LAGOON will serve as the confirmatory trial for lurbinectedin to secure full approval in the U.S. LAGOON will also be used as a registrational trial with the European Medicines Agency (EMA) to obtain marketing authorization in Europe.

PharmaMar Group increased its net cash position in 2021 to €167 million, from €163 million the previous year thus ending to December 31st, 2021 with cash and cash equivalents (cash and cash equivalents plus current and non-current financial investments) of €212 million and total debt of €45.5 million.

As a result, the PharmaMar Group reported net income of €93 million at the end of 2021.

The Board of Directors of Pharma Mar, S.A. will propose to the Shareholders' Meeting that a dividend in cash of €0.65 gross per Pharma Mar, S.A. share be paid to

shareholders against 2021 earnings, 8% higher than the dividend paid in the previous year.

Conference call on results for analysts and investors

PharmaMar will hold a conference call for analysts and investors on Tuesday, March 1st, 2022, at 13:00 (CET). The numbers to connect to the conference call are: +34 91 901 16 44 (from Spain), +1 646 664 1960 (from the US or Canada) or +44 20 3936 2999 (other countries). Participants' access code: 146916. To view the webcast, please click on the following link: https://streamstudio.world-television.com/1052-1618-31859/en.

The teleconference and the recording of the webcast can be accessed on PharmaMar's website by visiting the Events Calendar section of the Company's website at www.pharmamar.com.

About PharmaMar

PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation.

PharmaMar has developed and now commercializes Yondelis® in Europe by itself, as well as Zepzelca® (lurbinectedin), in the US; and Aplidin® (plitidepsin), in Australia, with different partners. In addition, it has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar has other clinical-stage programs under development for several types of solid cancers: lurbinectedin and ecubectedin. Headquartered in Madrid (Spain), PharmaMar has subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland and The United States. PharmaMar also wholly owns other companies: GENOMICA, a molecular diagnostics company; and Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

Media Contact:

Lara Vadillo – Communication Director lvadillo@pharmamar.com. Mobile: +34 669 47 18 03

Miguel Martínez-Cava – Comm. Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464

Phone: +34 918466000

Capital Markets & Investor Relations:

José Luis Moreno– Capital Markets & Investor Relations Director

María Marín de la Plaza – Capital Markets & Investor Relations

investorrelations@pharmamar.com
Phone: +34 914444500

Or please visit our website at www.pharmamar.com

REPORT AT 31 DECEMBER 2021

28 February 2022

MILESTONES IN 2021

Corporate

- Recurring revenue (sales plus royalties) increased by 27% with respect to 2020 year-end.
- Revenue in the Oncology segment amounted to €118.9 million, 18% more than in 2020 (€100.7 million).
- Royalties from sales of Yondelis® and Zepzelca by our partners in their respective territories amounted to €41.0 million, up from €15.7 million in 2020.
- Licensing revenues totaled €64.8 million, from the licensing agreement for Zepzelca signed with Jazz Pharmaceuticals in 2019 (€140.3 million in 2020).
- Operating cash flow amounted to €25.7 million in 2021.
- The net cash balance increased by €3.6 million year-on-year to €167 million.
- Creation of the PharmaMar Foundation

Oncology

- Lurbinectedin (Zepzelca)
  - New licensing and marketing agreements for the following territories:
    - Adium Pharma: 21 countries of Central and South America
    - Lotus Pharmaceutical: Taiwan
    - Eczasibasi Pharmaceuticals: Turkey
  - Our partners in the following countries obtained approval to market Zepzelca for treating small cell lung cancer:
    - Specialised Therapeutics Asia, Pte. Ltd (STA) received authorization from the Singapore Health Sciences Authority (HSA) to market Zepzelca in Singapore.
    - Immedica Pharma AB was authorized by the United Arab Emirates Ministry of Health and Prevention to market Zepzelca in the UAE.
    - Specialised Therapeutics Asia, Pte. Ltd (STA) received authorization from Australia's Therapeutic Goods Administration (TGA) to market Zepzelca in Australia.
    - Jazz Pharmaceuticals, Plc. received approval from Health Canada to commercialize Zepzelca in Canada.
  - Lurbinectedin received orphan drug designation for the treatment of mesothelioma
- Yondelis®
  - Our partner, Specialised Therapeutics Asia, Pte. Ltd. received authorization from Australia's Therapeutic Goods Administration (TGA) to market Yondelis® for treating liposarcoma and non-resectable or metastatic leiomyosarcoma

Diagnostics

- The qCOVID-19 Respiratory COMBO kit was validated for detecting SARS-CoV-2 in direct saliva samples. The kit, which offers a high level of sensitivity and specificity, is being marketed with the CE mark.

RNAi

- Enrolment of patients is advancing in the Phase III trial with SYL1001 in patients with dry eye disease associated with Sjögren's syndrome, which is being conducted in the United States.

- Enrolment has concluded in the Phase I trial on healthy volunteers with SYL1801 for treating choroid neovascularization associated with age-related macular degeneration (AMD) and diabetic retinopathy.

Mª Luisa de Francia
CFO
Pharma Mar, S.A.
Plaza Descubridor Diego de Ordás, 3
Madrid
Telephone 914444500

José Luis Moreno
Head of Capital Markets and Investor Relations
Pharma Mar, S.A.
Plaza Descubridor Diego de Ordás, 3
Madrid
Telephone 914444500

FIGURES TO DECEMBER 2021

	31/12/2021	31/12/2020	Change
RECURRING REVENUE	**164,817**	**129,400**	**27%**
Oncology sales	118,856	100,704	18%
Diagnostics sales	4,965	13,035	-62%
Oncology royalties	40,996	15,661	162%
NON-RECURRING REVENUE	**65,014**	**140,561**	**-54%**
Oncology out-licensing agreements	64,787	140,289	-54%
Other	227	272	-17%
TOTAL REVENUE	**229,831**	**269,961**	**-15%**

(Thousand euro)

Group revenue:

Recurring revenue, i.e. net sales plus royalties from sales by partners, increased by 27% year-on-year to €164.8 million in 2021 (from €129.4 million in 2020).

Net revenue in the Oncology segment amounted to €118.9 million, 18% more than in 2020 (€100.7 million). This increase is attributable to good sales performance by Zepzelca in Europe under the Temporary Authorisation for Use (TAU), which amounted to €30.2 million, a 40% increase on the €21.5 million reported in 2020. Net sales of Yondelis amounted to €69.4 million, a slight 0.7% decline on the 2020 figure, as a result of pricing pressure. It should be noted that gross sales of Yondelis in Europe increased by 3.7% year-on-year. Sales of Yondelis and Zepzelca raw materials to partners rose from €9.3 million in 2020 to €19.2 million in 2021 (+107%). Diagnostics revenues fell by €8 million year-on-year in 2021, affected by lower demand and the sharp decline in the price of COVID-19 diagnostics tests.

Royalty revenues amounted to €41.0 million in 2021, up from €15.7 million in 2020 (+162%). That figure includes royalties from Yondelis sales by our partners in the United States and Japan (€3.0 million) and from Zepzelca sales by our US partner Jazz Pharmaceuticals (€38.0 million in 2021). Royalties in the fourth quarter of 2021 are an estimate since the figures for sales by Jazz in that period were not available at the date of publishing this report.

Non-recurring revenue, mainly from out-licensing agreements, amounted to €64.8 million in 2021, compared with €140.3 million in 2020. This revenue in 2021 was principally from the recognition of €38.6 million in revenue out of the USD300 million collected in 2020 under the Zepzelca licensing agreement with Jazz Pharmaceuticals, which is being recognized in the income statement as a function of the fulfilment of contractual commitments. €22 million were due to the accounting recognition of a commercial milestone of the Jazz agreement. The €135.7 million in non-recurring revenue recognized in 2020 were due entirely to the agreement with Jazz Pharmaceuticals.

R&D

Group **R&D** expenditure increased by 34% year-on-year to €72.2 million in 2021 (from €53.8 million in 2020).

Oncology spent €61.1 million on R&D in 2021, including €19 million on clinical trials to develop plitidepsin (Aplidin) for the treatment of COVID-19, which are recognized in this segment. The Oncology area made progress in 2021 with trials of lurbinectedin in combination with other therapeutic agents; a new Phase III trial (LAGOON) was started in small cell lung cancer; other trials are being designed in a range of indications; new candidates are being readied for clinical trials; and early-stage research into new compounds continues

The RNAi segment increased R&D spending to €9.5 million in 2021, reflecting commencement of the first of two Phase III trials in the US with tivanisiran in dry eye disease associated with Sjögren's syndrome, as well as the Phase I trial in Spain with SYL18001 in macular degeneration.

The breakdown of R&D expenditure is shown in the next table:

	31/12/2021	31/12/2020	Difference	
R&D expenses	**72,170**	**53,792**	**18,378**	**34%**
Oncology	61,054	49,204	11,850	24%
Diagnostics	1,632	708	924	131%
RNAi	9,484	3,880	5,604	144%

(Thousand euro)

Other operating expenses

Other operating, commercial, administrative and corporate expenses amounted to €50.7 million in 2021, an increase of 7% with respect to 2020 (€47.3 million).

EBITDA

Group EBITDA amounted to €97.8 million in 2021 (€163.6 million in 2020).

	31/12/2021	31/12/2020
Net income	**92,859**	**137,262**
Income tax	2,270	8,344
Interest	(2,682)	10,338
Depreciation and amortization	5,305	7,660
EBITDA	**97,752**	**163,604**

(Thousand euro)

(EBITDA: earnings before interest, taxes, depreciation and amortization).

The variation in EBITDA, from €163.6 million in 2020 to €97.8 million in 2021, reflects the lower amount of revenue recognized in 2021 under the licensing agreement signed with Jazz Pharmaceuticals in December 2019 (€75 million less than in 2020). This was partly offset by higher sales and royalties (€35 million more than in 2020). Additionally, R&D expenditure increased by €18.4 million year-on-year.

Cash and Debt

As of 31 December 2021, cash and cash equivalents plus current and non-current financial assets amounted to €212.7 million (vs. €216.5 million as of 31 December 2020).

Loans from banks and official agencies amounting to €12.9 million were repaid in 2021, and new (mainly bank) loans were arranged in the amount of €5.8 million. Total interest-bearing debt declined by 14% (€7.4 million) with respect to 2020 year-end.

The net cash balance increased by 2.2% with respect to 2020 year-end.

For the purpose of comparing balance sheet figures, the Group's total net financial position at amortized cost is detailed below:

	31/12/2021	31/12/2020	Change
Non-current debt	**33,386**	**37,732**	**-4,346**
Bank loans	4,669	3,561	1,108
Bonds	16,654	16,600	54
Loans from official authorities	12,063	17,571	-5,508
Current debt	**12,212**	**15,313**	**-3,101**
Credit lines	3,745	4,771	-1,026
Bank loans	3,864	5,487	-1,623
Loans from official authorities	4,077	4,621	-544
Interest, etc.	526	434	92
Total interest-bearing debt	**45,598**	**53,045**	**-7,447**
Cash and cash equivalents plus current and non-current financial assets	**212,676**	**216,504**	**-3,828**
TOTAL NET CASH	**167,078**	**163,459**	**3,619**

(Thousand euro)

RESEARCH AND DEVELOPMENT IN 2021.

Below is an overview of research and development activities.

1.- Oncology segment: PharmaMar

Compounds:

A) Trabectedin (YONDELIS)

Soft tissue sarcoma

There were 21 post-authorization trials under way at the end of 2021, of which 14 were active. The other trials were in the process of closing and data analysis or were pending the presentation of results. Two additional trials are scheduled to commence in the coming months.

There were a number of publications in 2021 in connection with two trials with Yondelis that have concluded: One in *Annals of Oncology* with the results of the T-SAR Phase III trial comparing trabectedin with best supportive care, which was sponsored by the French Sarcoma Group; the results confirmed that Yondelis offers superior disease control compared with supportive care without limiting quality of life in soft tissue sarcoma patients. The other, in *Cancers*, with the results of the retrospective real-life trial sponsored by the Italian Sarcoma Group, which confirmed that Yondelis® offers clinical benefit to advanced sarcoma patients with multiple histologies.

At the ESMO Congress 2021 held in Paris on 16-21 September, the French Sarcoma Group presented data from a Phase III trial comparing trabectedin in combination with doxorubicin vs. the standard treatment of doxorubicin alone as first-line treatment for patients with metastatic or inoperable leiomyosarcoma (LMS). The arm consisting of trabectedin+doxorubicin attained a PFS of 13.5 months, compared with 7.3 months in the case of doxorubicin as monotherapy.
Four abstracts on trabectedin in soft tissue sarcoma were presented at the Connective Tissue Oncology Society (CTOS) meeting in November 2021. The Phase I trial by the Spanish Sarcoma Group (GEIS) with the combination of trabectedin+olaratumumab (OLATRASTS) was presented orally. This trial demonstrated that the combination is safe at the full recommended doses for both drugs; translational research into the samples is ongoing.

The results of the TRAMUNE Phase I-b trial with the durvalumab+trabectedin in soft tissue sarcoma or ovarian cancer, show that the combination is manageable and promising activity was observed in platinum-refractory ovarian cancer patients.

Ovarian cancer

A total of 11 trials in this indication were being managed in 2021; five of them are currently actively enrolling, and one is in the activation phase.

B) Lurbinectedin (ZEPZELCA)

Small-cell lung cancer

In December 2021, PharmaMar received approval from the first ethics committee in the United States to commence the pivotal Phase III trial as second-line treatment for relapsed small cell lung cancer (the LAGOON trial) that had been agreed upon with the FDA. This is a three-arm trial comparing lurbinectedin as monotherapy or in combination with irinotecan against investigator's choice of irinotecan, iv or oral topotecan. If the outcome is positive, the trial could confirm the benefits of lurbinectedin for treating small cell lung cancer when patients have experienced progression after first-line treatment with platinum in the USA and serve in a registrational capacity in other jurisdictions such as EMA.

Our partner, Jazz Pharmaceuticals, has announced the enrolment of the first patient for the IMforte Phase III trial to assess Zepzelca® in combination with a PD-L1 inhibitor for treating small cell lung cancer. The trial, which is sponsored by Jazz and co-financed by Roche, will measure progression-free survival and general survival with Zepzelca® in combination with atezolizumab as compared with atezolizumab as monotherapy.

The results of the ATLANTIS Phase III clinical trial were selected for presentation by Dr. Paz-Ares in a Presidential Symposium at the International Association for the Study of Lung Cancer (IASLC) virtual World Conference on Lung Cancer 2021, held on 11-14 September. There was also an oral presentation and four posters on lurbinectedin at that meeting.

Combination trials with Zepzelca (lurbinectedin)

In 2021, recruitment continued on schedule for the Phase I trial with lurbinectedin in combination with either irinotecan, pembrolizumab or atezolizumab.

At the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which was held online in November, Dr. Santiago Ponce presented a poster with the results of the Phase I trial in combination with atezolizumab in patients with small cell lung cancer. The combination obtained very good levels of activity combined with a manageable toxicity profile.

PharmaMar presented new data from the trial with lurbinectedin in combination with irinotecan in patients with endometrial cancer at the ASCO 2021 Virtual Meeting in June. The data showed that the combination of lurbinectedin with irinotecan is effective in patients with advanced endometrial cancer after failure of more than one line of therapy.

Phase I trial in China

The trial being conducted by our partner, Luye, to ascertain the dose of ZEPZELCA® in Chinese patients ended patient enrolment and is currently in the monitoring phase.

C) Ecubectedin (PM14)

The World Health Organization (WHO) has confirmed the International Nonproprietary Name (INN) of PM14 as ecubectedin.

The main endpoint of the Phase I trial with ecubectedin is to identify the optimal dose for administration in patients with advanced solid tumors, define the compound's safety profile, and assess its pharmacokinetics and pharmacogenetics in treated patients. Patient enrolment continues in the expansion phase in selected tumors.

Combination trials

The Phase I/II trial with this compound in combination with irinotecan continues enrolment satisfactorily, and enrolment for the Phase Ib trial in combination with atezolizumab commenced in December 2021.

D) Virology Unit: Plitidepsin (APLIDIN®)

Aplidin (plitidepsin)

The NEPTUNE multicenter, randomized, controlled Phase III clinical trial to determine the efficacy and safety of two dosages of plitidepsin versus control in adult patients requiring hospitalization for the treatment of moderate COVID-19 infection continues with patient enrolment in Spain and nine other countries, mainly in Europe and Latin America.

The definitive results of the APLICOV-PC Phase I-II trial with plitidepsin against COVID-19 were published in Life Science Alliance. They showed that plitidepsin is safe to administer to COVID-19 patients and suggest a positive therapeutic impact on the course of the disease. The trial achieved its primary endpoint, safety, and evidenced clinical effectiveness. The NEPTUNE Phase III trial was designed on the basis of those results.

2.- Diagnostics Genómica

Genómica ended 2021 with €5.2 million in net revenue, compared with €13.2 million in 2020. That decrease was due to lower revenue from COVID-19 tests (PCR, antigen and antibody) as a result of increased competition and the consequent sharp decline in prices. Sales of non-COVID diagnostics tests (papillomavirus, herpes virus, respiratory infections, STDs, etc.) have not yet regained pre-pandemic levels. Improving pandemic figures suggest that results will improve in the coming quarters.

The qCOVID-19 Respiratory COMBO kit was validated in January for detecting SARS-CoV-2 in direct saliva samples. The kit, which offers a high level of sensitivity and specificity, is being marketed with the CE mark.

The analysis time required using the CLART® technology was shortened from four to two hours. The first product in which this improvement was implemented is Fast CLART® Pneumovir, which has been on the market since December. This kit is capable of detecting 21 respiratory viruses, including five coronaviruses, one of which is SARS-CoV-2. The kit was validated at several Spanish hospitals and offers over 95% sensitivity and specificity.

Additionally, we have signed distribution agreements for our products in Mexico and Scandinavia.

3.- RNA interference: Sylentis

Clinical development of tivanisiran for treating dry eye syndrome continued in 2021. In February, we received the green light to commence a Phase III trial with SYL1001 in dry eye disease associated with Sjögren's syndrome, an autoimmune disease. Over 30 hospitals in the US are participating and the trial plans to recruit 200 patients. This is a randomized, double-blind, placebo-controlled trial whose primary and secondary end-points are, respectively, the efficacy (signs and symptoms) and safety of tivanisiran in patients with dry eye disease associated with Sjögren's syndrome. The first patient was enrolled in this trial in May and enrolment continue advancing. During the year, PharmaMar obtained a full waiver from the FDA for a pediatric trial with tivanisiran in dry-eye syndrome.

Additionally, a Phase I trial with healthy volunteers commenced with SYL1801 for the treatment and/or prevention of choroid neovascularization associated with pathologies such as age-related macular degeneration (AMD) and diabetic retinopathy. This trial, being conducted at Hospital Universitario Ramón y Cajal in Madrid, completed enrolment in December, having attained the full complement of healthy volunteers. The trial will assess the safety of several doses of SYL1801 and the product's pharmacokinetics. Work is under way to design a forthcoming Phase II trial in patients with AMD.

The company is also using Sylentis's proprietary SirFINDER 2.0 software to find other RNAi candidates for topical treatment of retinal diseases. Those new candidates' efficacy continues to be assessed using preclinical models of a number of retinal pathologies.

CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION *(Thousand euro)*	December 31, 2021	December,30 2020
ASSETS		
Non-current assets		
Property, plant and equipment	26.961	21.947
Investment property	845	845
Intangible assets	3.233	3.860
Right-of-use assets	3.644	3.552
Non-current financial assets	10.722	20.988
Deferred tax assets	27.750	33.416
	73.155	**84.608**
Current assets		
Inventories	10.536	11.933
Trade and other receivables	50.908	24.054
Financial assets at amortised cost	88.532	99.306
Other assets	31.907	14.148
Cash and cash equivalents	113.348	96.210
	295.231	**245.651**
TOTAL ASSETS	**368.386**	**330.259**

CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION *(Thousand euro)*	*December 31, 2021*	*December,30 2020*
EQUITY		
Share capital	11.013	11.013
Share premium	71.278	71.278
Treasury shares	(25.679)	(21.453)
Revaluation reserves	19	14
Retained earnings and other reserves	121.287	41.870
Total capital and reserves attributable to equity holders of the parent company	**177.918**	**102.722**
TOTAL EQUITY	**177.918**	**102.722**
LIABILITIES		
Non-current liabilities		
Borrowings	33.386	37.732
Lease liabilities	1.916	2.150
Non-current deferred income	68.634	92.560
Other non-current liabilities	186	176
	104.122	**132.618**
Current liabilities		
Trade and other payables	29.269	23.220
Borrowings	12.212	15.313
Lease liabilities	1.819	1.470
Outstanding remunerations	7.546	6.411
Current deferred income	29.667	43.603
Other current liabilities	5.833	4.902
	86.346	**94.919**
TOTAL LIABILITIES	**190.468**	**227.537**
TOTAL EQUITY AND LIABILITIES	**368.386**	**330.259**

CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS		
(Thousand euro)	December 31, 2021	December 31, 2020
Revenue:		
Revenue from contracts with customers	123.821	113.739
Revenue from licensing and development agreements	64.787	140.289
Royalties	40.996	15.661
Other	227	272
	229.831	**269.961**
Cost of sales	(16.437)	(13.718)
Gross profit	**213.394**	**256.243**
Marketing expenses	(22.368)	(22.257)
General and administrative expenses	(17.371)	(13.515)
Research and development expenses	(72.170)	(53.792)
Net impairment on financial assets	96	(267)
Other operating expenses	(10.928)	(11.576)
Other results	1.794	1.108
Operating loss	**92.447**	**155.944**
Finance costs	(7.683)	(15.376)
Finance income	10.365	5.038
Finance costs - net	**2.682**	**(10.338)**
Result of the period before income taxes	**95.129**	**145.606**
Income tax benefit / (expense)	(2.270)	(8.344)
Result for the period	92.859	137.262
Result is attributable to:		
Equity holders of the parent company	92.859	137.262

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW (Thousand euro)	December 31, 2021	December 31, 2020
Result before taxes:	**95.129**	**145.606**
Adjustments for:	**2.822**	**17.833**
Depreciation and amortization	5.583	7.211
Provision for impairment of accounts receivable	(93)	16
Impairment losses of property, plant and equipment	(183)	368
Finance income	(370)	(336)
Finance costs	3.373	3.124
Results on disposals of intangible assets	33	31
Share based payments	339	274
Deferred income - grants	(186)	(405)
Exchange differences on translation of foreign operations	(5.674)	7.550
Changes in working capital:	**(61.408)**	**127.941**
Inventories	1.398	(3.031)
Trade and other receivables	(26.761)	(12.630)
Other assets and liabilities	(5.555)	5.694
Trade and other accounts payable	7.185	4.654
Deferred or accrual items	(37.675)	133.254
Other cash flows from operations:	**(10.866)**	**(12.438)**
Interest paid	(3.373)	(3.124)
Interest received	370	336
Income taxes paid	(7.863)	(9.650)
Net cash outflow from operating activities	**25.677**	**278.942**
Acquisitions:	**(7.803)**	**(119.009)**
Property, plant and equipment, intangible assets and investment property	(7.803)	(3.002)
Other financial assets	-	(116.007)
Proceeds from:	**26.275**	**-**
Other financial assets	26.275	-
Net cash inflow from investing activities	**18.472**	**(119.009)**
Receipts and (payments) in connection with equity instruments:	**(7.105)**	**(33.462)**
Ordinary shares amortization	-	(120)
Purchase of treasury shares	(40.659)	(63.708)
Proceeds from shares issued	33.554	30.366
Receipts and (payments) in connection with financial liabilities:	**(9.438)**	**(31.539)**
Proceeds from borrowings	5.832	834
Repayment of borrowings	(15.270)	(32.373)
Dividends paid	**(10.872)**	**(8.819)**
Net cash inflow (outflow) from financing activities	**(27.415)**	**(73.820)**
Effects of exchange rate changes on cash and cash equivalents	**404**	**(7.541)**
Net increase (decrease) in cash and cash equivalents	**17.138**	**78.572**
Cash and cash equivalents at beginning of the period	96.210	17.638
Cash and cash equivalents at end of the period	**113.348**	**96.210**